ImmuneOncia Therapeutics Statistics
Total Valuation
KOSDAQ:424870 has a market cap or net worth of KRW 512.91 billion. The enterprise value is 474.38 billion.
| Market Cap | 512.91B |
| Enterprise Value | 474.38B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
KOSDAQ:424870 has 73.91 million shares outstanding. The number of shares has increased by 20.04% in one year.
| Current Share Class | 73.91M |
| Shares Outstanding | 73.91M |
| Shares Change (YoY) | +20.04% |
| Shares Change (QoQ) | -18.78% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 20.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 669.81 |
| PB Ratio | 10.80 |
| P/TBV Ratio | 11.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -77.06 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -25.85 |
Financial Position
The company has a current ratio of 11.33, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.33 |
| Quick Ratio | 9.95 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -3,313.17 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -26.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 6,030.80 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 67.85 |
| Average Volume (20 Days) | 5,845,980 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KOSDAQ:424870 had revenue of KRW 765.75 million and -6.16 billion in losses. Loss per share was -98.40.
| Revenue | 765.75M |
| Gross Profit | 754.31M |
| Operating Income | -12.91B |
| Pretax Income | -6.16B |
| Net Income | -6.16B |
| EBITDA | -11.95B |
| EBIT | -12.91B |
| Loss Per Share | -98.40 |
Balance Sheet
The company has 38.59 billion in cash and 69.48 million in debt, giving a net cash position of 38.53 billion or 521.28 per share.
| Cash & Cash Equivalents | 38.59B |
| Total Debt | 69.48M |
| Net Cash | 38.53B |
| Net Cash Per Share | 521.28 |
| Equity (Book Value) | 47.51B |
| Book Value Per Share | 642.78 |
| Working Capital | 41.62B |
Cash Flow
In the last 12 months, operating cash flow was -18.32 billion and capital expenditures -24.16 million, giving a free cash flow of -18.35 billion.
| Operating Cash Flow | -18.32B |
| Capital Expenditures | -24.16M |
| Free Cash Flow | -18.35B |
| FCF Per Share | -248.27 |
Margins
| Gross Margin | 98.51% |
| Operating Margin | -1,686.12% |
| Pretax Margin | -803.92% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KOSDAQ:424870 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.04% |
| Shareholder Yield | -20.04% |
| Earnings Yield | -1.20% |
| FCF Yield | -3.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KOSDAQ:424870 has an Altman Z-Score of 55.23 and a Piotroski F-Score of 1.
| Altman Z-Score | 55.23 |
| Piotroski F-Score | 1 |